Evidence check: CYP1A2 in the context of weight loss

The role of CYP1A2 in weight loss is not strongly supported by evidence. CYP1A2 encodes an enzyme that metabolizes caffeine. Some studies suggest that genetic variants (e.g., rs762551) influence caffeine clearance and may modulate the thermogenic effect of caffeine, but findings are inconsistent. Most evidence is mechanistic or from small observational studies; large randomized trials are lacking. Lifestyle factors (caffeine intake, sleep, exercise) likely override any small genetic effect. Direct weight loss recommendations based solely on CYP1A2 genotype are not evidence-based. Consumers should be cautious of DTC tests that oversimplify 'metabolic types' for marketing. A holistic approach including diet, physical activity, and medical supervision remains essential.